Related to NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses

• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• MedImmune Nabs Rights to IDC’s GLA Adjuvant for Infectious Disease Vaccines
  
• Inviragen and Duke-NUS Form Vaccine Partnership to Tackle Emerging Infectious Diseases
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• Crucell to Use Pepscan’s CLIPS Technology for Development of Infectious Disease Vaccines
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• DoD Pledges $4.6M to Establish Infection Genomics Center at UTSA
  
• $3M NIAID Grant Will Fund Inviragen Collaboration with UTMB to Develop Chikungunya Vaccine
  
• CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand
  
• CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program
  
• Medicago Achieves Fourth Milestone in Setting Up U.S. cGMP Facility for Plant-Expressed Vaccines
  
• GSK Confirms £500M Investment in Manufacturing Across Multiple U.K. Sites
  
• Baxter to Invest $1B in Construction of New Plasma Products Facility in Georgia
  
• Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
  
• BioFactura Scores Nearly $2M for Ebola Therapy and VRP Vaccine Production
  
• Cobra Spinout Prokarium Acquires Emergent IP to Boost Oral Vaccine Initiative
  
• New Malaria Vaccine in the Works
  
• Protecting Newborns from RSV by Immunizing Moms-to-Be
  
• Study Shines a Light on Colorectal Cancer
  
• NIH Stem Cell Center to Use Horizon's GENESIS Technology